Management of neuropsychiatric adverse events in a prostate cancer patient undergoing chimeric antigen receptor T-cell immunotherapy (a phase I clinical trial): A case report

In previous clinical trials, chimeric antigen receptor T-cell immunotherapy has shown preliminary efficacy in patients with malignant solid tumors. However, the occurrence of adverse events, particularly neuropsychiatric adverse events (eg, anxiety) and cognitive dysfunction, during the course of treatment may reduce patient compliance and pose a threat to their safety. Nurses are in a unique position to promptly identify and manage such complications, thereby facilitating early diagnosis and treatment, as well as improving clinical and patient outcomes. Moreover, nurses can promote compliance through the provision of psychological support to patients.